Filing and reporting period
Entity discrepancy: The request identifies IMMUNIC, INC., but the supplied Form 10-Q is for Vital Therapies, Inc. This summary reflects the filing provided. It covers the quarter ended March 31, 2016; financial statements are unaudited.
Vital Therapies is a clinical-stage biotherapeutic company developing ELAD, an extracorporeal cell-based therapy for acute liver failure. It reported no revenue from planned principal operations.
Key financial metrics
Amounts are in millions of dollars unless noted. There is no reported product revenue, gross profit, or operating margin; the company remained loss-making.
| Metric | Q1 2016 / March 31, 2016 | Comparable period / prior balance |
|---|---|---|
| Research and development expense | $6.857 | $11.753 in Q1 2015 |
| General and administrative expense | $2.799 | $3.064 in Q1 2015 |
| Total operating expenses | $9.656 | $14.817 in Q1 2015 |
| Net loss | $9.589 | $14.758 in Q1 2015 |
| Basic and diluted loss per share | $0.31 | $0.62 in Q1 2015 |
| Operating cash flow | $(9.956) | $(13.506) in Q1 2015 |
| Cash and cash equivalents | $77.876 | $83.416 at December 31, 2015 |
| Total current assets / current liabilities | $79.239 / $4.816 | $85.088 / $6.655 at December 31, 2015 |
| Total assets / stockholders’ equity | $82.920 / $78.048 | $89.081 / $82.325 at December 31, 2015 |
Q1 investing activities provided $0.090 million; financing activities provided $4.327 million, primarily from ATM share sales. Cash decreased by $5.540 million during the quarter. No debt balance is separately reported in the presented balance sheet; the filing text does not provide a clear debt metric.
Changes versus the prior comparable period
Operating expenses declined 35% year over year. R&D expense fell $4.896 million, primarily because clinical-trial, manufacturing, and consulting costs were $4.5 million lower as the company discontinued VTI-210 and VTI-212 and shifted to VTL-308. Reduced staffing also lowered compensation costs. G&A expense declined 9%, largely from lower consulting, travel, and salary costs, partly offset by higher stock-based compensation.
Net loss narrowed by $5.169 million, and operating cash use declined by $3.550 million year over year. Cash nevertheless fell from year-end, reflecting operating outflows partly offset by equity financing.
Outlook, risks, and unusual items
- Clinical program: The pivotal VTI-208 trial failed to meet its primary and secondary endpoints. The company discontinued VTI-210 and VTI-212 and is pursuing VTL-308, a Phase 3 trial in severe acute alcoholic hepatitis, designed using analyses of VTI-208 results. No VTL-308 subjects were enrolled in Q1. Management expected first enrollment in the first half of 2016, at least 150 subjects across about 40 sites, and top-line results around mid-2018.
- Funding outlook: Management estimated that March 31 cash, together with approximately $2.3 million net proceeds from April ATM sales, would fund operations into Q1 2018, assuming limited BLA activity and no significant commercial infrastructure buildout. It anticipated raising additional funds before VTL-308 top-line data. Funding needs and runway depend on trial enrollment, costs, and other factors; no external funding source was committed.
- Equity financing: Q1 ATM sales generated approximately $4.3 million net. In April, the company sold a further 264,234 shares at a weighted average price of $9.17, with estimated net proceeds of $2.3 million. The company disclosed substantial remaining shelf and ATM capacity, creating potential dilution.
- Litigation: A putative securities class action alleges misleading statements concerning the relationship and implications of the company’s clinical trials. The court consolidated the actions and appointed a lead plaintiff on May 2, 2016. The company said it could not reasonably estimate a loss range and recorded no liability; legal costs are expensed as incurred.
- Principal risks: VTL-308 may not succeed or support regulatory approval; regulators may require another pivotal trial. Other key risks include enrollment delays, manufacturing and supplier constraints, adverse events, limited financing options, and the company’s dependence on ELAD as its sole product candidate. Management expected R&D and G&A costs to rise from Q1 levels during the remainder of 2016.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Vital Therapies, Inc., not IMMUNIC, INC.
- Check VTL-308 enrollment, site activation, trial design, and progress against the expected timeline and top-line data target.
- Monitor cash burn, financing activity, dilution, and whether the stated runway remains achievable.
- Review developments in the securities litigation and any change in the company’s ability to estimate potential loss.
- Assess whether trial results, manufacturing readiness, and regulatory feedback address the risks following VTI-208’s failure.